Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03592264
Title This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OBI Pharma, Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Scripps Clinic Torrey Pines La Jolla California 92037 United States Details
USC Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field